A Randomized Phase 3 Study of MRTX849 Versus Docetaxel in Patients With Previously Treated Non-Small Cell Lung Cancer With KRAS G12C Mutation - A Phase 3 Study of MRTX849 vs Docetaxel in Advanced NSCLC

Mirati Therapeutics, Inc.0 个研究点目标入组 450 人开始时间: 2021年5月27日最近更新: 2024年7月15日

适应症

试验速览

暂无简介。

•Histologically or cytologically confirmed diagnosis of NSCLC with KRAS G12C mutation.
•Candidacy to receive treatment with docetaxel.
•Crossover Inclusion Criteria
•1. Evidence of RECIST 1.1 defined disease progression on docetaxel per BICR.
•2.0 ECOG performance status 0-2.
•Are the trial subjects under 18? no
•Number of subjects for this age range:
•F.1.2 Adults (18-64 years) yes
•F.1.2.1 Number of subjects for this age range 225
•F.1.3 Elderly (>=65 years) yes
•F.1.3.1 Number of subjects for this age range 225

•Prior treatment with an agent targeting KRAS G12C (e.g., AMG 510).
•Active brain metastases.
•Crossover Inclusion Criteria
•1. Receipt of any systemic anti-cancer therapy after last administration of docetaxel on the study.

发起方